HPV Prevalence and Prognostic Value in a Prospective Cohort of 255 Patients with Locally Advanced HNSCC: A Single-Centre Experience

Abstract

Background. HPV is a positive prognostic factor in HNSCC. We studied the prevalence and prognostic impact of HPV on survival parameters and treatment toxicity in patients with locally advanced HNSCC treated with concomitant chemoradiation therapy. Methods. Data on efficacy and toxicity were available for 560 patients. HPV was detected by PCR. Analysis was performed using Kaplan-Meier survival curves, Fisher's test for categorical data, and log-rank statistics for failure times. Results. Median follow-up was 4.7 years. DNA extraction was successful in 255 cases. HPV prevalence was 68.6%, and 53.3% for HPV 16. For HPV+ and HPV−, median LRC was 8.9 and 2.2 years (P = 0.0002), median DFS was 8.9 and 2.1 years (P = 0.0014), and median OS was 8.9 and 3.1 years (P = 0.0002). Survival was different based on HPV genotype, stage, treatment period, and chemotherapy regimen. COX adjusted analysis for T, N, age, and treatment remained significant (P = 0.004). Conclusions. Oropharyngeal cancer is increasingly linked to HPV. This study confirms that HPV status is associated with improved prognosis among H&N cancer patients receiving CRT and should be a stratification factor for clinical trials including H&N cases. Toxicity of CRT is not modified for the HPV population.

Clinical characteristics and outcomes of oropharyngeal carcinoma related to high‐risk non–human papillomavirus16 viral subtypes

“…In contrast to many prior studies, in which HPV18 was the most prevalent type after HPV16, HPV35, and HPV33, were the second and third most common types in our retrospective analysis. We can only speculate as to why our genotype frequencies are different, this could potentially be related to either the highly international urban catchment of this single center study, 15,22,23 or failure of many other studies to test for HPV genotypes beyond HPV16 and HPV18. It seems likely that the incidence of highrisk non-HPV16 OPC may be determined both by their relative frequency in the population and other unknown factors, including genetic predisposition, which we have shown to influence HPV-related OPC risk, 24 and potential environmental influences.…”

Human papillomavirus in oropharyngeal cancer in Canada: analysis of 5 comprehensive cancer centres using multiple imputation

“…5 However, a study in London, Ontario, was restricted to patients with tonsillar cancer for whom a pathology specimen was available; 17 one study in Toronto included only 22 patients with oropharyngeal cancer; 18 other Toronto-based studies either took place before routine HPV testing 12 or focused on recurrent or metastatic disease; 19 and one study in Montréal analyzed patients with locally advanced cancer who were treated with primary chemoradiation and had a minimum 3-year follow-up. 20 A previous study of 1374 Ontario-based patients with oropharyngeal cancer suggested that 66% of cases were HPV-positive by 2010. 1 Given the limitations of these previous studies, a more comprehensive study across multiple Canadian centres was warranted.…”

“…(24) 165 (22) 50 (13) 84 (25) 408 (26) 26 (22) 4 629 (20) 76 (10) 96 (24) 58 (17) 375 (24) 24 (20) Nodal (N) stage n = 3149 n = 751 n = 391 n = 336 n = 1550 n = 121 0 596 (19) 178 (24) 73 (19) 24 (7) 303 (20) 18 (15) 1 406 (13) 108 (14) 57 (14) 53 (16) 178 (11) 10 (8) 2 1898 (60) 397 (53) 239 (61) 226 (67) 952 (61) 84 (69) 3 249 (8) 68 (9) 22 (6) 33 (10) 117 (8) 9 (8) TNM stage n = 3157 n = 754 n = 396 n = 336 n = 1550 n = 121…”

Investigation of Detected by Recent Various Human Papillomavirus from General Hospital in Seoul Area

“…But recently used to the various sample preparation with ThinPrep, cervical brushing, formalin fixed tissue. In general, fourteen HPV genotypes (HPV 16,18,31,33,35,39,45,51,52,56,58,59,66,and 68) are considered pathogenic or "high-risk (HR)" for causing the development of cervical cancer [2]. Cytology-based cervical cancer screening was introduced decades ago and subsequently implemented in many industrialized countries.…”

“…After cell lysis the target mRNA is isolated from the specimen by sequence-specific capture oligomers that also contain a deoxyadenosine tail. Many reported that being performed to prevalence of HPV positive ratio, for preventing the development of cervical cancer [17][18][19].…”